- Home
- CHEK vs CHRO Comparison
CHEK vs CHRO Comparison
Compare CHEK & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- CHRO
- Stock Information
- Founded
- CHEK 2004
- CHRO 2002
- Country
- CHEK Israel
- CHRO United States
- Employees
- CHEK N/A
- CHRO N/A
- Industry
- CHEK Medical Electronics
- CHRO
- Sector
- CHEK Health Care
- CHRO
- Exchange
- CHEK Nasdaq
- CHRO Nasdaq
- Market Cap
- CHEK 5.1M
- CHRO 4.2M
- IPO Year
- CHEK 2015
- CHRO 2024
- Fundamental
- Price
- CHEK $0.61
- CHRO $0.63
- Analyst Decision
- CHEK
- CHRO Strong Buy
- Analyst Count
- CHEK 0
- CHRO 1
- Target Price
- CHEK N/A
- CHRO N/A
- AVG Volume (30 Days)
- CHEK 14.0K
- CHRO 121.3K
- Earning Date
- CHEK 02-14-2025
- CHRO 11-13-2024
- Dividend Yield
- CHEK N/A
- CHRO N/A
- EPS Growth
- CHEK N/A
- CHRO N/A
- EPS
- CHEK N/A
- CHRO N/A
- Revenue
- CHEK N/A
- CHRO N/A
- Revenue This Year
- CHEK N/A
- CHRO N/A
- Revenue Next Year
- CHEK N/A
- CHRO N/A
- P/E Ratio
- CHEK N/A
- CHRO N/A
- Revenue Growth
- CHEK N/A
- CHRO N/A
- 52 Week Low
- CHEK $0.61
- CHRO $0.45
- 52 Week High
- CHEK $3.45
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- CHEK 19.90
- CHRO 48.49
- Support Level
- CHEK $0.61
- CHRO $0.55
- Resistance Level
- CHEK $0.63
- CHRO $0.71
- Average True Range (ATR)
- CHEK 0.04
- CHRO 0.10
- MACD
- CHEK -0.00
- CHRO -0.00
- Stochastic Oscillator
- CHEK 0.00
- CHRO 23.98
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.